Vistagen (NASDAQ: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company today announced that CEO Shawn Singh, The Goldie Hawn Foundation Founder Goldie Hawn, and children from New York City schools using The Goldie Hawn Foundation’s MindUp, a neuroscience-based preventative mental health program for youth, will jointly ring the Nasdaq Closing Bell on October 10, 2024. The joint ceremony will commemorate World Mental Health Day and The Goldie Hawn Foundation’s 20th Anniversary. The ceremony will highlight the power of collaboration and shared commitment to advance neuroscience-based innovation.
“At Vistagen, we believe in the importance of a multifaceted approach to improving mental health through heightened awareness, innovative education, and improved patient care,” said Shawn Singh, CEO of Vistagen. “Driven by pioneering neuroscience-based research, Vistagen and MindUp can make a positive difference in the mental health and well-being of millions of children and adults around the world.”
To view the full press release, visit https://ibn.fm/SvvQM
About Vistagen Therapeutics Inc.
Vistagen is a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders. Based on its pioneering approach and deep understanding of nose-to-brain neurocircuitry, Vistagen’s diversified neuroscience pipeline includes non-systemic pherine nasal spray product candidates designed to rapidly activate chemosensory neurons in the nasal cavity to impact olfactory system and brain neurocircuitry. Vistagen’s most advanced pherine candidate, fasedienol, is in a U.S. registration-directed Phase 3 development program for the acute treatment of social anxiety disorder, which affects over 30 million adults in the U.S. Vistagen is passionate about creating novel and differentiated treatments that set new standards of care for millions of people living with anxiety, depression, and other neurological disorders. For more information, visit the company’s website at www.Vistagen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About TinyGems
TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered by IBN
